Intraventricular Hemorrhage Therapeutics Registry
Having now completed enrollment in the CLEAR-III clinical trial, we are launching a clinical registry to track worldwide adoption of the therapy and techniques that were evaluated during the phase III clinical trial. It is hoped that this registry will help stroke researchers and scientists gain valuable information about the use of intraventricular thrombolytic therapy as it is generalized to community hospitals and specialized stroke centers around the world, many of which may not have participated in the CLEAR III clinical trial.
Neurosurgeons, neurologists and neurointensivists worldwide who are working in the field of hemorrhagic stroke are invited to apply for participation. This registry does not collect any personally-identifiable patient health information (PHI) and therefore should not require a HIPAA release. Cases are identified only by a unique sequential number, subject age (if under 90 years old), gender and race. There are no patient-related dates being collected. This registry has been approved by Johns Hopkins University Institutional Review Board (IRB00059240, 23-Jan-2015) as an international clinical research registry; you should check with your local IRB/EC to see if any local approval may be needed.
Hypothesis: Intraventricular thrombolysis for Intraventricular Hemorrhage can be conducted with comparable efficacy and safety in a non-clinical trial setting as compared to CLEAR-III.
Inclusion Criteria: Adults (at least 18 years old) being treated for spontaneous intraventricular hemorrhage (IVH) with obstruction of 3rd and/or 4th ventricle(s). Subjects with structural vascular brain lesions (tumor, moyamoya, AVM, aneurysm, etc.) should be excluded.
TO ACCESS VIA A WEB BROWSER, you can click here to load it in your browser. If you do this from your phone, you can then save it as a "web app" on your phone. From Safari on the iPhone, click the SHARE button, then select ADD TO HOME SCREEN.
©Copyright 2015 Emissary International LLC on behalf of Johns Hopkins University
The design, programming, content and layout of the IVH Therapeutics App is proprietary.
Authorization for use in this project is granted only to approved participating investigators.